article
19 September 2018 | By Iryna Karaban, Iryna Mankovska, Kateryna Rozova, Larysa Bratus, Olga Gonchar
Mitochondrial dysfunction has been widely implicated in the neuronal degeneration in Parkinson’s disease (PD). Mitochondria-targeted protective compounds that prevent or minimise a wide range of mitochondrial defects constitute potential therapeutic strategies in the prevention and treatment of neuronal degeneration in PD.